Brimonidine/timolol

Brimonidine/timolol
Combination of
Brimonidine	α₂ adrenergic agonist
Timolol	Beta blocker
Clinical data
Trade names	Combigan
AHFS/Drugs.com	entry
Pregnancy category	US: C (Risk not ruled out)
Legal status	US: ℞-only
Routes of administration	Eye drops
Identifiers
ATC code	S01ED51
PubChem	CID 11387895

Brimonidine/timolol (INNs, trade name Combigan) are combination eye drops indicated for the treatment of glaucoma. It is a combination of brimonidine (an α₂ adrenergic agonist) and timolol (a β adrenergic blocker), in concentrations of 0.2% and 0.5% respectively. Both substances work by decreasing the synthesis of aqueous humor.

Combigan is marketed and sold by Allergan.

Drugs used for glaucoma preparations and miosis (S01E)

Sympathomimetics

Parasympathomimetics

muscarinic	Aceclidine Pilocarpine

muscarinic/nicotinic	Acetylcholine Carbachol

Acetylcholinesterase inhibitors	Demecarium Ecothiopate Stigmine (Fluostigmine Neostigmine Physostigmine) Paraoxon

Carbonic anhydrase inhibitors/
(sulfonamides)

Beta blocking agents

Prostaglandin analogues (F_2α)

Other agents

This article is issued from Wikipedia - version of the Thursday, July 17, 2014. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.